| A GAF-domain-regulated adenylyl cyclase from Anabaena is a self-activating cAMP switch T Kanacher, A Schultz, JU Linder, JE Schultz The EMBO Journal 21 (14), 3672-3680, 2002 | 152 | 2002 |
| A defined subset of adenylyl cyclases is regulated by bicarbonate ion MJ Cann, A Hammer, J Zhou, T Kanacher Journal of Biological Chemistry 278 (37), 35033-35038, 2003 | 125 | 2003 |
| A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation C Thiel, S Schneckener, M Krauss, A Ghallab, U Hofmann, T Kanacher, ... Journal of pharmaceutical sciences 104 (1), 191-206, 2015 | 121 | 2015 |
| Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug–drug interactions and co-medication regimens D Moj, N Hanke, H Britz, S Frechen, T Kanacher, T Wendl, WE Haefeli, ... The AAPS journal 19, 298-312, 2017 | 45 | 2017 |
| A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, s-mephenytoin … T Kanacher, A Lindauer, E Mezzalana, I Michon, C Veau, JDG Mantilla, ... Pharmaceutics 12 (12), 1191, 2020 | 21 | 2020 |
| CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans N Chattopadhyay, T Kanacher, M Casjens, S Frechen, S Ligges, ... British Journal of Clinical Pharmacology 84 (12), 2857-2866, 2018 | 21 | 2018 |
| Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives T Stengel, T Maier, A Mann, J Stadlwieser, D Flockerzi, A Pahl, ... | 6 | 2015 |
| A physiologically-based Pharmacokinetic (PB-PK) model to explore ALX-0171 PK in infants following inhalation M Germani, C Niederalt, T Kanacher, T Stohr, L Detalle, T Wendl, ... Fifth American conference on pharmacometrics, 2014 | 5 | 2014 |
| Die Adenylatcyclase CyaB1 aus Anabaena sp. PCC 7120 ist ein cAMP-sensitives Protein T Kanacher Universität Tübingen, 2003 | 5 | 2003 |
| Method for Identifying PDE5-Modulators T Kanacher, J Linder, J Schultz US Patent App. 11/596,990, 2009 | 3 | 2009 |
| Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives T Stengel, T Maier, A Mann, J Stadlwieser, D Flockerzi, A Pahl, ... US Patent App. 14/958,141, 2016 | | 2016 |
| Nuevos derivados de ftalacinonapirrolopirimidincarboxamida T Stengel, T Maier, A Mann, J Stadlwieser, D Flockerzi, A Pahl, ... | | 2016 |
| Nouveaux dérivés de phtalazinone-pyrrolopyrimidinecarboxamide T Stengel, T Maier, A Mann, J Stadlwieser, D Flockerzi, A Pahl, ... | | 2014 |
| Compuestos derivados de ftalazinona-pirrolo [3, 2-d] pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion … T Stengel, T Maier, A Mann, J Stadlwieser, D Flockerzi, A Pahl, ... | | 2014 |
| Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida M Viertelhaus, T Stengel, T Maier, A Mann, D Flockerzi, A Pahl, ... | | 2014 |
| Novedosos derivados de ftalazinona-pirrolopririmidinacarboxamida T Stengel, T Maier, A Mann, J Stadlwieser, D Flockerzi, A Pahl, ... | | 2014 |
| Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida T Dunkern, A Hatzelmann, J Stadlwieser, RP Hummel, C Zitt, D Flockerzi, ... | | 2014 |
